TrialAdvances in therapy2023

Podcast on Lorlatinib as a First-Line Treatment Option for Patients with ALK-Positive Metastatic NSCLC with Brain Metastasis.

Geoffrey Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.